Better Short-Term Results With LADG in Stomach Cancer
A study found that patients who undergo minimally invasive laparoscopic gastrectomy are better able to tolerate chemotherapy for gastric cancer... Read More
SATURDAY, NOVEMBER 16
Peninsula Golf & Country Club
701 Madera Drive San Mateo, California
&
PURCHASE TICKETS
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Antibiotic use before cancer treatment cuts survival time study
Taking antibiotics in the month prior to starting immunotherapy for cancer can lessen the chance of survival, an important finding... Read More
Survival Benefit of Palliative Gastrectomy Followed by Chemotherapy for Stage IV Gastric Signet Ring Cell Carcinoma – copy
A study found a high rate of H. Pylori in patients undergoing sleeve gastrectomy for weight loss. That suggests there’s... Read More
ESMO Clinical Practice Guidelines for Surveillance of Hereditary Gastrointestinal Cancers
The European Society for Clinical Oncology (ESMO) issued new recommendations for screening patients who may face a high risk of... Read More
PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
Expression of the coding RNA PCAT-1 is associated with cisplatin resistance in gastric cancer, and suppressing PCAT-1 can re-sensitize cancer... Read More
Survival Benefit of Palliative Gastrectomy Followed by Chemotherapy for Stage IV Gastric Signet Ring Cell Carcinoma
Gastrectomy followed by chemotherapy can be more effective than chemo alone in gastric cancer patients with signet ring cell carcinoma,... Read More
Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1
Scientists in China discovered that low expression of a particular MicroRNA called miR-628 is associated with lymph-node metastasis and poor... Read More
Checkpoint Inhibitor Checks in as Treatment for Advanced Gastric Cancers
Despite mixed results in clinical trials, Keytruda is producing promising survival results in some gastric cancer patients and has promise... Read More
Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals announced positive results from a phase 3 study of Repretinib in gastrointestinal stromal tumors.-
Doctors at NYU Langone Hospital—Brooklyn Help Patient with Rare Stomach Cancer Turn His Life Around
NYU gastroenterologists are using advanced imagery and robotic surgery techniques to improve the detection and removal of stomach tumors. 
Optimal Duration of First-Line Chemotherapy for Advanced Gastric Cancer: Data from the AGAMENON Registry
A study concludes that longer first-line chemotherapy regimens for patients with gastric cancer has a protective effect, and that discontinuing... Read More
The diagnostic value of serum gastrokine 1 (GKN1) protein in gastric cancer
A new study finds that levels of the protein gastrokine 1 (GKN1) in the blood can serve as a biomarker... Read More-
Gastric cancer risks due to CDH1 variant likely overestimated
A new study suggests that people with CDH1 mutations might not be at as high a risk for gastric cancer... Read More 
In JAMA Oncology Publication, GeneDx Describes Lower Lifetime Risk of Gastric Cancer Conferred by CDH1
A study by GeneDx shows that the lifetime risk for gastric cancer in people with pathogenic CDH1 variants is 42%... Read More
Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer
In a recent trial of checkpoint inhibitors in gastric or esophageal cancer, patients who reported immune-related side effects also showed... Read More
Oncologie Pairs PS Inhibitor Bavituximab with Merck’s Keytruda for Gastric Cancer
A new clinical trial pairs Oncologie’s bavituximab with Merck’s Keytruda in advanced stomach or gastroesophageal cancer.-
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics announced that a combination of its experimental drug DKN-01 and Merck’s Keytruda had a 50% overall response rate... Read More -
GCF-AGA Grant Recipient El-Zaatari Charts Progress on Three Research Efforts
Ever since Mohamad El-Zaatari, Ph.D., research assistant professor at the University of Michigan, received the first GCF-American Gastroenterology Association grant... Read More 
Helicobacter pylori infection, chronic atrophic gastritis and riskof stomach and esophagus cancer: Results from the prospec tivepopulation-based ESTHER cohort study
A cohort study involving nearly 10,000 patients found that infection with H. Pylori in the presence of chronic atrophic gastritis... Read More
Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.